Organization
1Metroplex Clinical Research Center, dallas
1 abstract
Abstract
BIOSIMILAR CANDIDATE ABP 501: ADDITIONAL EFFICACY ANALYSES FROM THE PHASE 3 STUDY Org: 1Metroplex Clinical Research Center, dallas, Amgen Inc., Thousand Oaks, United States of America,